Meril Life Sciences

Vapi, Gujarat, India All India companies → — Founded 2006

Healthcare Conglomerate Medical Device / Hardware Specialty-Focused AI

Orthopedics

Surgical AI

Private Equity — $410M

Website Claim this company

Products

MISSO Robotic

Meril Life Sciences

Surgical AI

MISSO Robotic System is an advanced AI-powered surgical robotic system designed to enhance precision, safety, and patient outcomes in joint replacement surgeries through AI-driven planning, real-time feedback, and precise robotic execution.

Paid

See all 1 product →

About Meril Life Sciences

Meril Life Sciences is an Indian multinational medical device company dedicated to the innovation, design, and development of clinically relevant and state-of-the-art devices. The company focuses on alleviating human suffering and improving the quality of life through advanced healthcare solutions. Meril’s extensive product portfolio spans various medical fields, including vascular intervention, orthopedic implants, robotics, endosurgery, ENT products, and in-vitro diagnostics.

Meril Life Sciences is committed to advancing healthcare through continuous innovation, with a strong emphasis on research and development. The company operates a large-scale, certified infrastructure with over 150 dedicated R&D professionals and holds more than 500 patents. Their R&D efforts are geared towards addressing unmet clinical needs globally, developing next-generation treatment modalities, and creating disruptive technologies. Meril also runs the Meril Academy, which provides education and training to healthcare personnel, bridging the gap between technological advancements and practical implementation.

In the realm of healthcare AI, Meril Life Sciences is actively leveraging artificial intelligence and machine learning to revolutionize surgical planning and execution, ultimately enhancing patient outcomes. Their AI-powered robotic systems, such as the MISSO Robotic System for orthopedic joint replacement procedures and the MIZZO Endo 4000 for soft-tissue minimally invasive procedures, utilize advanced data analytics to generate precise 3D models and optimized surgical plans. These systems aim to improve accuracy, minimize human error, and provide real-time feedback during surgery, leading to better surgical outcomes and faster recovery.

Focus Areas

vascular intervention orthopedic implants robotics endosurgery ENT products in-vitro diagnostics AI-driven interventions surgical robotics cardiovascular structural heart

Business Intelligence

Key Investors	Warburg Pincus, Abu Dhabi Investment Authority (ADIA), Bilakhia Group, Bilakhia Holdings
Partnerships	Japan Lifeline
Acquisitions	Maxx Orthopedic (2009)
Technology	AI-powered robotic systems, advanced data analytics, machine learning algorithms for diagnostics and treatment planning, cloud-native (implied by digital supply chain initiatives)
FDA Clearances	unknown cleared products (estimated)

What Physicians Need to Know

Vascular Intervention

Meril Life Sciences offers a diverse portfolio of vascular intervention devices, including drug-eluting stents, bioresorbable scaffolds (like the MeRes100u2122 BRS, India's first domestically produced bio-resorbable scaffold), balloon catheters, and transcatheter aortic valve replacement (TAVR) systems (such as the Myval THV series and Myval Octapro THV). They also provide devices for peripheral vascular intervention, focusing on minimally invasive treatments for diseases affecting blood vessels outside the heart. Their products are backed by clinical studies and global scientific advisors.

Orthopedic Implants

Meril specializes in orthopedic implants designed to restore mobility, offering a wide range of products including total hip and knee replacement systems (like the FREEDOMu00ae Total Knee System and OPULENTu2122 BIONIK GOLD KNEE IMPLANT), revision surgery devices, trauma, and spine devices. They utilize advanced design engineering technologies and extensive clinical research. Their implants are designed to accommodate diverse anatomies and sizing.

Robotics & AI-Driven Interventions

Meril is at the forefront of developing robotic and AI-driven interventions, including surgical robots, service robots, and AR/VR robots. Their offerings include the MISSO robotic-assisted surgical system for orthopedic joint replacement procedures, which uses AI-driven planning, real-time feedback, and precise robotic execution. They also have the MIZZO Endo 4000, an advanced soft-tissue surgical robotic system for minimally invasive procedures across multiple specialties, featuring AI-based 3D visualization and 5G-enabled telesurgery. The HandX platform merges robotic dexterity with ergonomic design for endosurgery.

Endosurgery

Meril's endosurgery division develops innovative products using cutting-edge technology. Their portfolio includes absorbable and non-absorbable surgical sutures, tissue sealants, absorbable hemostats, hernia repair meshes, intrauterine devices, and mechanical closure devices like staplers (e.g., MIRUS range). They focus on enhancing surgical capabilities and addressing practical challenges in diverse healthcare environments.

ENT Products

Meril's ENT division focuses on throat and rhinology-related medical devices and minimally invasive technologies. Their current portfolio includes treatments for chronic sinusitis, airway management solutions, balloon treatments of tracheal stenosis, and management technology for tonsils and adenoids.

In-Vitro Diagnostics

Meril's diagnostics division leverages advanced technology to deliver clinically researched medical devices, covering central labs, hospitals, and home testing devices, including over-the-counter products. They manufacture diagnostic equipment, reagents, and rapid tests for diseases such as Dengue, HIV 1 and 2, hCG, Ag, HCV, and Malaria.

Structural Heart

Meril is a key player in structural heart solutions, with innovations like the Myval transcatheter aortic valve system for treating aortic stenosis and the MyClip device for mitral valve repair via the transcatheter edge-to-edge repair (TEER) procedure. They are committed to advancing interventional cardiology through science-led innovation and clinical excellence.

Cardiovascular

Meril offers a comprehensive array of cardiovascular devices, including mechanical and bioprosthetic heart valves for aortic valve replacement, mitral valve replacement, and double valve replacement. They also provide an intra-coronary shunt for bloodless operative fields during bypass graft surgeries and the Myosistu2122 Intra-Aortic Balloon Catheter Kit for hemodynamic stabilization in critical cardiac conditions.

Physician Tip

Meril Life Sciences stands out for physicians due to its strong commitment to research and development, resulting in a pipeline of innovative, clinically-backed medical devices across multiple specialties. Their focus on AI and robotic technology, such as the MISSO robotic-assisted surgical system and MIZZO Endo 4000, offers enhanced precision, control, and improved patient outcomes, particularly in joint replacement and minimally invasive procedures. Meril also emphasizes collaboration with medical professionals globally in the design and development of their products, ensuring they address unmet clinical needs. The company's dedication to making robotic technology and devices more affordable and accessible is also a key differentiator. Furthermore, Meril Academy provides education and training programs for healthcare personnel, fostering skill development and knowledge sharing.

Meril Life Sciences' robotic systems, such as MIZZO Endo 4000, incorporate AI-based 3D visualization and are designed with a 5G-enabled telesurgery framework, suggesting potential for advanced integration with digital surgical platforms and remote assistance capabilities. Their AI-powered diagnostic tools and wearable devices also indicate a focus on data analysis and real-time insights, which could integrate with electronic health records (EHR) and other health monitoring systems for personalized treatment and predictive healthcare. The company's emphasis on collaborative innovation within the Meril ecosystem, including working with surgical specialty divisions and establishing clinical programs and partnerships, suggests an openness to integrating their technologies within broader healthcare workflows and systems.

At a glance

Founded 2006

HQ Vapi, Gujarat, India · India

Team size 10000+

CEO Vivek Shah

Funding Private Equity — $410M

FDA clearances unknown (estimated)

Products 1

Visit site

Products by Meril Life Sciences

1 product in the directory

MISSO Robotic

Meril Life Sciences

Surgical AI

Paid

What the Web Says

Meril Life Sciences is an Indian multinational medical device company founded in 2006, specializing in vascular intervention devices, orthopedic implants, robotics, endosurgery, ENT products, and in-vitro diagnostics. The company has a global presence, operating in over 150 countries and employing more than 10,000 people as of 2024. Reviews indicate a generally positive work culture and management, with opportunities for freshers and mid-level managers. However, some employees express concerns about career growth and work-life balance.

Overall: Mixed

Strengths

Good work culture and empathic management.
Ample opportunities and exposure for freshers and mid-level managers.
Excellent work-life balance for employees at the Vapi, Gujarat headquarters.
Good benefits and salary for some positions.
Strong brand value in the medical device industry.
Supportive environment and management.

Limitations

Less strategy and career growth.
Poor salary structure and no growth for some executive roles.
No work-life balance for some employees, with unofficial working hours often exceeding official hours.
High working capital-intensive operations due to high inventory and debtor cycles.
Exposure to regulatory risks and ongoing patent infringement litigation.
Boring work environment and not much to learn for some.

Based on reviews from: Indeed.com, Reddit, Wikipedia, ICRA Limited, PharmaBharat, The Hindu

Last updated: 2026-10-01

Videos

News, demos, and interviews about Meril Life Sciences.

Loading videos...

Videos load interactively. If none appear, search YouTube for Meril Life Sciences →

View all on YouTube

Press & Coverage

News on Projects

ADIA Injects $200 Million into India's Meril Life Sciences, Valuing MedTech Firm at $6.6 Billion.

A wholly-owned subsidiary of the Abu Dhabi Investment Authority (ADIA) has invested $200 million for a 3% stake in Meril Life Sciences, valuing the company at $6.6 billion. This investment will accelerate Meril's growth and R&D efforts in advanced healthcare solutions.

2025-07

Healthcare Radius

Meril launches MyClip, India's First Transcatheter-Edge-to-Edge Repair System for Treatment of Severe Mitral Regurgitation.

Meril Life Sciences has launched MyClip, India's first Transcatheter-Edge-to-Edge Repair (TEER) system for treating severe mitral regurgitation. This product launch expands Meril's portfolio in structural heart solutions.

2025-06

Medical Dialogues

Meril Life Sciences announces LANCET publication for landmark RCT of MYVAL THV series, researched and developed by India

Meril Life Sciences announced the publication of the LANDMARK trial study in The Lancet, showcasing its indigenously developed Myval Transcatheter Heart Valve (THV) series. The research compares early outcomes of the new-generation Myval THV series with contemporary THV series in patients with severe symptomatic native aortic stenosis.

2024-06

PR Newswire

Meril Life Sciences Presents One-year Outcomes from the LANDMARK Randomized Controlled Trial at PCR London Valves 2025

Meril Life Sciences presented the one-year outcomes from the LANDMARK Randomized Controlled Trial at PCR London Valves 2025, with results also published in the Journal of the American College of Cardiology (JACC). The study demonstrated the non-inferiority of the Myval THV series for clinical efficacy.

2025-11

Fenwick

U.S. Supreme Court Won't Disturb Meril Life Sciences' Patent Victory Under the Safe Harbor

The U.S. Supreme Court declined to review a case, solidifying Meril Life Sciences' patent victory under the safe harbor exemption. This precedent confirms the safe harbor applies to preparatory activities for FDA submissions, such as recruiting clinical trial investigators.

2025-01

Meril Life Sciences (Blog)

Meril Life Sciences and Japan Lifeline Join Forces for Global Expansion

Meril Life Sciences has partnered with Japan Lifeline to expand its global presence, granting Japan Lifeline exclusive rights to introduce Meril's Myval Octacor transcatheter heart valve in Japan after PMDA approval. This collaboration aims to advance cardiovascular solutions globally.

unknown

Business Standard

Meril launches indigenously developed knee-replacement robotic system.

Meril Life Sciences has launched MISSO, an indigenously developed knee-replacement robotic system, priced significantly lower than other available systems in the Indian market. This marks a significant advancement in surgical robotics.

2022-02

Meril Life Sciences

Meril Receives CE Mark for MeRes100 Bioresorbable Scaffold

Meril Life Sciences became the first Indian company to receive the European Conformity (CE) mark for its 100-micron bioresorbable vascular scaffold (BVS), MeRes100. This non-metallic mesh is designed to open blocked arteries and gradually dissolve.

unknown

Frequently Asked Questions

What is Meril Life Sciences' core focus in vascular intervention, and what specific products do you offer for cardiologists and interventional radiologists?

Meril Life Sciences is deeply committed to vascular intervention, offering a comprehensive portfolio that includes coronary stents (e.g., EverMINE, EverMINE50), balloon catheters, and guidewires. Our products are designed to address a range of cardiovascular conditions, focusing on improving patient outcomes in percutaneous coronary interventions (PCI). We aim to provide innovative and high-quality solutions for complex vascular anatomies and lesions.

Can you elaborate on Meril's orthopedic implant offerings, particularly regarding joint replacement and spine solutions, and how they compare to competitors in terms of innovation and patient outcomes?

Meril Life Sciences provides a robust range of orthopedic implants, including solutions for total knee replacement (e.g., Meril GENESIS, Meril GENESIS PC), total hip replacement, and spinal fixation systems. Our focus is on biocompatibility, longevity, and advanced design to enhance patient mobility and reduce recovery times. We differentiate ourselves through continuous R&D, aiming for superior clinical performance and patient satisfaction compared to other market players.

What advanced technologies, such as AI-driven interventions and surgical robotics, does Meril Life Sciences integrate into its product lines, and how do these enhance surgical precision and efficiency?

Meril Life Sciences is at the forefront of integrating advanced technologies like AI-driven interventions and surgical robotics to enhance precision and efficiency across our product lines. While specific product names for AI and robotics are continually evolving, our commitment is to leverage these innovations to improve surgical accuracy, minimize invasiveness, and optimize patient recovery in areas like cardiovascular and orthopedic procedures. These technologies are designed to provide surgeons with enhanced control and real-time data for better decision-making.

How does Meril Life Sciences ensure product compliance with international regulatory standards (e.g., FDA, CE) and what is your approach to post-market surveillance and product support?

Meril Life Sciences adheres to stringent international regulatory standards, including CE marking and various national approvals, for all our medical devices. We maintain a robust quality management system that encompasses design, manufacturing, and post-market surveillance to ensure product safety and efficacy. Our commitment to compliance is unwavering, and we provide comprehensive product support and vigilance to address any post-market concerns promptly and effectively.

What is Meril Life Sciences' strategy for pricing and partnerships, especially for large healthcare networks or integrated delivery systems, and what kind of support can we expect for product implementation and training?

Meril Life Sciences offers competitive and transparent pricing strategies, often tailored through partnerships with large healthcare networks and integrated delivery systems to provide cost-effective solutions. We are dedicated to fostering strong collaborations and offer extensive support for product implementation, including comprehensive training for physicians and clinical staff. Our goal is to ensure seamless integration of our products and optimal utilization within your healthcare environment.

Beyond cardiovascular and orthopedics, what are Meril's key offerings in endosurgery, ENT products, and in-vitro diagnostics, and what makes these solutions stand out?

Beyond our core areas, Meril Life Sciences offers innovative solutions in endosurgery, ENT products, and in-vitro diagnostics. In endosurgery, we focus on minimally invasive instruments and devices that enhance surgical precision and patient recovery. Our ENT product line addresses various ear, nose, and throat conditions with advanced surgical tools. For in-vitro diagnostics, we provide reliable and accurate diagnostic kits and systems crucial for timely disease detection and management. These offerings stand out due to their focus on advanced technology, user-friendliness, and clinical efficacy.

Related Companies

Suggest an Edit →